During the project, CliniWorks AccelFind software will be interfaced to Southampton’s clinical systems to extract and de-identify information about cancers, heart and blood conditions, and other diseases from one million records. It will also collect and structure information on diagnoses, treatments, medications and outcomes into a format that supports research and clinical trials.
Adrian Byrne, Southampton’s chief information officer, said: “Southampton is already a leader in involving patients in research programmes and we are happy that we can work with iSOFT to improve this and ensure that more patients obtain access to the latest and best treatments.”
iSOFT signalled its intent to move into the life sciences space, after agreeing a deal with US-based CliniWorks for AccelFind, which is developed to extract medical knowledge from any type of data, including free text notes, discharge summaries or the structured data found in electronic medical records.
“Drug development is an extremely expensive business and typically costs up to US$1 billion to bring a single drug to market,” Kraenzlein said.
“The process of recruiting patients for clinical trials is the most critical element, causing 80% of trials to run over time and budget, with an average of 90 days and £1.3 million in lost sales, so anything that reduces time and cost will interest pharmaceutical companies greatly.
“Through our partnership with Southampton and CliniWorks, we can move to developing solutions which will speed the feasibility and patient recruitment processes and so help execute trials on time and budget.”
iSOFT’s chief medical officer, Dr Michael Dahlweid, said: “This is a beacon project which paves the way for healthcare organisations to move beyond collecting data for use during patient care, to using the data for advanced analysis, prediction and improved drug discovery. The potential benefits to patients are significant.”